Original ArticleEffect of Riluzole on Spinal Cord Regeneration with Hemisection Method Before Injury
Introduction
Riluzole is a neuroprotective drug that blocks glutamatergic neurotransmission, and it has gained popularity because of its safety and efficacy in patients with amyotrophic lateral sclerosis.1, 2, 3, 4, 5 Riluzole blocks voltage-gated sodium channels and calcium ion channels and inhibits glutamate release in the nervous system,5, 6, 7, 8, 9, 10, 11, 12, 13 which has been shown to be potentially protective.1, 14, 15, 16, 17 It also has been studied for use in spinal cord injury (SCI), and experimental studies in animals have underlined the decrease in tissue destruction and increase in functional recovery after riluzole use.18, 19, 20
SCI may be due to traumatic injuries, tumors, infections, and nontraumatic causes such as spondylosis.4 Its pathophysiology is biphasic: the primary acute phase develops concurrently with traumatic injury and consists of necrosis and apoptosis, whereas secondary damage is a result of primary damage that begins with activation of endogenous cell death pathways.21, 22, 23 Those in the primary phase present with mechanical tissue damage immediately after trauma, so no intervention may help. However, secondary damage begins with a tissue damage response, which is revealed especially by glutamate-mediated excitotoxicity, and it can be interrupted by suspension of these pathways.24
The North American Clinical Trials Network Consortium (NACT) conducted systematic studies of reports published between 1966 and 2011 regarding pharmacologic therapies for SCI. The NACT Treatment Strategy Selection Committee has suggested that 5 drugs are effective for treating SCI: riluzole, glyburide, magnesium sulfate, nimodipine, and minocycline.24
We studied the effect of riluzole in the treatment of SCI. According to our knowledge, riluzole has not been administered in SCI prior to injury. Additionally, the effect of Riluzole onneural degeneration was firstly investigated using spinal cord hemisectionmodel which imitates the neural degeneration mechanisms in a most realistic way. We questioned whether riluzole may be beneficial and may contribute to functional recovery when used in the preoperative period in patients who are at high risk for permanent neurologic deficit.
Section snippets
Experimental Groups
All experimental procedures used in this investigation were reviewed and approved by the ethical committee of the Ankara University and conformed to the National Institutes of Health Guidelines for Care and Use of Experimental Animals. Riluzole was administered intraperitoneally at a dose of 6 mg/kg. A total of 32 adult male Wistar albino rats weighing 210–250 g were assigned randomly to 8 groups with 4 rats per group: group 1, riluzole solvent (HCl + NaOH + saline; riluzole solution is needed
Results
We studied 32 albino Wistar rats, with each group containing four animals. Two rats (groups 7 and 8) died at the end of the week. The average weight of the remaining 30 rats was 228.13 ± 10 g (minimum 210 g, maximum 246 g). There was no significant difference in the average weights of the group (P > 0.05, Kruskal–Wallis χ2 tests).
Investigation of the Effectiveness of Riluzole
In a current meta-analysis of SCI, riluzole was demonstrated to have significant clinical effects in experimental animal models.22, 23 In these studies, riluzole was given after SCI, which was performed via ischemia,26 weight reduction,27 clipping,18 and balloon compression.19 Two situations make our study important. First, in our study, the hemisection method was used for the first time to investigate the effectiveness of riluzole on neural regeneration in a rat SCI model. Second, for the
Conclusions
The pathophysiology of SCI with the information obtained to date has not been fully elucidated. Specific treatment has not been found in SCI to prevent local or remote damage (neural protection) and for regeneration. A safe drug or treatment protocol that results in cell regeneration is not known for SCI.
Neuroprotective and neuroregenerative effects of riluzole, which is in a trial phase, given after SCI have been shown in experimental studies. In our study, histopathologic and clinic results
References (45)
- et al.
Role of synaptic and nonsynaptic glutamate receptors in ischaemia induced neurotoxicity
Brain Res Bull
(2015) Glutamate release and neuronal damage in ischemia
Life Sci
(2001)- et al.
Association of Riluzole and dantrolene improves significant recovery after acute spinal cord injury in rats
Spine J
(2018) - et al.
Riluzole improves outcome following ischemia–reperfusion injury to the spinal cord by preventing delayed paraplegia
Neuroscience
(2014) - et al.
Riluzole prevents ischemic spinal cord injury caused by aortic crossclamping
J Thorac Cardiovasc Surg
(1999) - et al.
Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury
J Clin Neurosci
(2007) - et al.
Functional reorganization of the forepaw cortical representation immediately after thoracic spinal cord hemisection in rats
Exp Neurol
(2014) - et al.
Time course quantification of spastic hypertonia following spinal hemisection in rats
Neuroscience
(2010) - et al.
Time-related changes of motor unit properties in the rat medial gastrocnemius muscle after the spinal cord injury. II. Effects of spinal cord hemisection
J Electromyogr Kinesiol
(2010) - et al.
Co-treatment with Riluzole and GDNF is necessary for functional recovery after ventral root avulsion injury
Exp Neurol
(2004)
Delayed Riluzole treatment is able to rescue injured rat spinal motoneurons
Neuroscience
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Cochrane Database Syst Rev
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group
N Engl J Med
Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II
Lancet
Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS)
PLoS One
The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis
Drug Deliv
A review of neuroprotective agents
Curr Med Chem
Neurocytotoxicity: pharmacological implications
Fundam Clin Pharmacol
Pathophysiology and treatment of focal cerebral ischemia. Part I: pathophysiology. (1992)
J Neurosurg
Prophylactic riluzole attenuates oxidative stress damage in spinal cord distraction
J Neurotrauma
Mechanism of neuroprotection against experimental spinal cord ınjury by riluzole or methylprednisolone
Neurochem Res
Delayed spinal cord-brachial plexus reconnection after C7 ventral root avulsion: the effect of reinnervating motoneurons rescued by riluzole treatment
J Neurotrauma
Cited by (13)
Neuroprotective effects of Riluzole and Curcumin in human astrocytes and spinal cord white matter hypoxia
2020, Neuroscience LettersCitation Excerpt :Riluzole, an FDA approved drug for amyotrophic lateral sclerosis (ALS), is in a clinical trial for SCI and has been shown to be a promising pharmacological intervention to attenuate the devastating effects of injury [32,41]. It is shown to be more effective when provided before injury; thus, it can contribute to functional recovery when used in the preoperative period in patients who are at a high risk for permanent neurologic deficit [3]. In addition, riluzole has been shown to significantly improve locomotor scores, gait function, and neuropathic pain in preclinical models of traumatic and non-traumatic SCI [35].
Pediatric Spinal Cord Injury: A Review
2023, ChildrenRiluzole in Progressive Cerebellar Ataxias
2023, Contemporary Clinical NeuroscienceA mechanistic overview of spinal cord injury, oxidative DNA damage repair and neuroprotective therapies
2023, International Journal of Neuroscience
Conflict of interest statement: The authors declare that the article content was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.